Background: New methods to increase measles and rubella (MR) vaccination coverage are needed to achieve global and regional MR elimination goals. Methods: Here, we developed microneedle (MN) patches designed to administer MR vaccine by minimally trained personnel, leave no biohazardous sharps waste, remove the need for vaccine reconstitution, and provide thermostability outside the cold chain. This study evaluated the immunogenicity of MN patches delivering MR vaccine to infant rhesus macaques. Results: Protective titers of measles neutralizing antibodies (>120 mIU/mL) were detected in 100% of macaques in the MN group and 75% of macaques in the subcutaneous (SC) injection group. Rubella neutralizing antibody titers were >10 IU/mL for all groups. All macaques in the MN group were protected from challenge with wild-type measles virus, whereas 75% were protected in the SC group. However, vaccination by the MN or SC route was unable to generate protective immune responses to measles in infant macaques pretreated with measles immunoglobulin to simulate maternal antibody. Conclusions: These results show, for the first time, that MR vaccine delivered by MN patch generated protective titers of neutralizing antibodies to both measles and rubella in infant rhesus macaques and afforded complete protection from measles virus challenge.
Background: New methods to increase measles and rubella (MR) vaccination coverage are needed to achieve global and regional MR elimination goals. Methods: Here, we developed microneedle (MN) patches designed to administer MR vaccine by minimally trained personnel, leave no biohazardous sharps waste, remove the need for vaccine reconstitution, and provide thermostability outside the cold chain. This study evaluated the immunogenicity of MN patches delivering MR vaccine to infantrhesus macaques. Results: Protective titers of measles neutralizing antibodies (>120 mIU/mL) were detected in 100% of macaques in the MN group and 75% of macaques in the subcutaneous (SC) injection group. Rubella neutralizing antibody titers were >10 IU/mL for all groups. All macaques in the MN group were protected from challenge with wild-type measles virus, whereas 75% were protected in the SC group. However, vaccination by the MN or SC route was unable to generate protective immune responses to measles in infant macaques pretreated with measles immunoglobulin to simulate maternal antibody. Conclusions: These results show, for the first time, that MR vaccine delivered by MN patch generated protective titers of neutralizing antibodies to both measles and rubella in infantrhesus macaques and afforded complete protection from measles virus challenge.
Authors: Helen L Quinn; Mary-Carmel Kearney; Aaron J Courtenay; Maelíosa T C McCrudden; Ryan F Donnelly Journal: Expert Opin Drug Deliv Date: 2014-07-14 Impact factor: 6.648
Authors: Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz Journal: Lancet Date: 2017-06-27 Impact factor: 79.321
Authors: Reinaldo de Menezes Martins; Birute Curran; Maria de Lourdes Sousa Maia; Maria das Graças Tavares Ribeiro; Luiz Antonio Bastos Camacho; Marcos da Silva Freire; Anna Maya Yoshida Yamamura; Marilda Mendonça Siqueira; Maria Cristina F Lemos; Elizabeth Maciel de Albuquerque; Vanessa dos Reis von Doellinger; Akira Homma; Laura Saganic; Courtney Jarrahian; Michael Royals; Darin Zehrung Journal: Contemp Clin Trials Date: 2014-12-01 Impact factor: 2.226
Authors: Sean P Sullivan; Dimitrios G Koutsonanos; Maria Del Pilar Martin; Jeong Woo Lee; Vladimir Zarnitsyn; Seong-O Choi; Niren Murthy; Richard W Compans; Ioanna Skountzou; Mark R Prausnitz Journal: Nat Med Date: 2010-07-18 Impact factor: 53.440
Authors: Ryan F Donnelly; Kurtis Moffatt; Ahlam Zaid Alkilani; Eva M Vicente-Pérez; Johanne Barry; Maelíosa T C McCrudden; A David Woolfson Journal: Pharm Res Date: 2014-02-19 Impact factor: 4.200
Authors: Dimitrios G Koutsonanos; E Stein Esser; Sean R McMaster; Priya Kalluri; Jeong-Woo Lee; Mark R Prausnitz; Ioanna Skountzou; Timothy L Denning; Jacob E Kohlmeier; Richard W Compans Journal: Vaccine Date: 2015-03-03 Impact factor: 3.641
Authors: Khanh T M Tran; Tyler D Gavitt; Nicholas J Farrell; Eli J Curry; Arlind B Mara; Avi Patel; Lindsey Brown; Shawn Kilpatrick; Roxana Piotrowska; Neha Mishra; Steven M Szczepanek; Thanh D Nguyen Journal: Nat Biomed Eng Date: 2020-11-23 Impact factor: 25.671
Authors: Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke Journal: Trials Date: 2022-09-14 Impact factor: 2.728
Authors: Gavin B Grant; Balcha G Masresha; William J Moss; Mick N Mulders; Paul A Rota; Saad B Omer; Abigail Shefer; Jennifer L Kriss; Matt Hanson; David N Durrheim; Robert Linkins; James L Goodson Journal: Vaccine Date: 2019-03-20 Impact factor: 3.641
Authors: Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland Journal: Expert Rev Vaccines Date: 2018-12-26 Impact factor: 5.683
Authors: Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo Journal: Expert Opin Drug Deliv Date: 2020-10-06 Impact factor: 8.129
Authors: Wen-Hsuan W Lin; Eileen Moran; Robert J Adams; Robert E Sievers; Debra Hauer; Steven Godin; Diane E Griffin Journal: Sci Transl Med Date: 2020-04-01 Impact factor: 17.956